ABCG2 and myeloproliferative disorder: Moreover, flow cytometry analyses showed a strong trend of higher percentages of ABCG2-positive RBCs in MPN patients prior to any treatment compared to healthy individuals (Figure 1D, p = 0.06) further validating our mass spectrometry data from untreated patients [11].